Skip to main content

Ciphergen to Develop Breast Cancer Diagnostics

NEW YORK, Dec. 9 (GenomeWeb News) - Ciphergen Biosystems said yesterday that it is developing breast cancer diagnostics based on a "series of discoveries" that have been made using the company's SELDI technology.


Ciphergen cited a study by researchers at the Johns Hopkins School of Medicine, published in Clinical Chemistry in 2002, that detailed the discovery of three serum biomarkers that can improve the detection of breast cancer.


"Two out of the three markers have since been identified and validated in further studies that were published this month," the company said in a statement. The markers are named C3a and BC1.


Ciphergen said it plans to expand upon these studies in a collaboration with the University of College London and UCL BioMedica that will analyze samples collected from 200,000 women with breast and ovarian cancer.


Ciphergen did not provide a timeline for the development program.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.